“Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is driving the overall growth of the clinical trial supplies market”
The global clinical trial supplies market is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2021, at a CAGR of 8.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the increasing R&D expenditure in pharmaceutical and biopharmaceutical companies and the growing number of clinical trials conducted globally. However, the increasing cost of drug development and clinical trials is expected to restrain the growth of this market during the forecast period.
“The logistics and distribution segment accounted for the highest growth rate in the clinical trial supplies market, by service, during the forecast period”
In 2020, the logistics & distribution services segment accounted for the largest share (26.3%) of the clinical trial supplies market, mainly due to the globalization of clinical trials, the increasing number of trials involving temperature-sensitive products, the highly regulated nature of the market, and expertise of supply companies in terms of therapeutic areas and geographical reach. The growth of the fastest-growing segment was attributed to the increasing number of clinical trials conducted and the decentralization of the trials across the globe.
“Oncology segment accounted for the largest share of the therapeutic area segment”
Based on the therapeutic area, the clinical trial supplies market is segmented into oncology, CNS & mental disorders, cardiovascular diseases, digestive disorders, infectious diseases, metabolic disorders, immunology, blood disorders, and other therapeutic areas (respiratory disorders, dermatological disorders, rare diseases, ENT diseases, Nephrology) Oncology is the largest segment in this market owing to the high and growing number of research studies on cancer therapeutics and the increasing number of companies focusing on bringing innovative cancer drugs into the market. Also, the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting innovative diagnostic and therapeutic approaches is a driver. In this scenario, effective drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors, many pharmaceutical companies are making significant investments in the development of innovative cancer drugs.
“Asia Pacific: The fastest-growing region in the clinical trial supplies market”
The clinical trial supplies market is segmented into North America, Europe, Asia Pacific, RoW The APAC market, on the other hand, is expected to be the fastest-growing regional segment during the forecast period owing to increasing investments and expansions by big pharma companies in countries such as China, India, and South Korea.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80%and Demand Side 20%
- By Designation: C-level – 25%, D-level – 20%, and Others – 55%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
- Thermo Fisher (US)
- Catalent, Inc. (US)
- Parexel (US)
- Eurofins (France)
- UDG Healthcare (Ireland)
- Piramal Pharma Solutions (India)
- Almac Group (UK)
- PCI Pharma Services (US)
- PRA Health Sciences (US)
- Biocair (UK), Eurofins (France)
- Marken (US)
- Infosys (India)
- Liveo Research (India)
- Capsugel (a Lonza Group company) (Switzerland)
- SIRO Clinpharm (India)
- KLIFO A/S (Denmark)
- Clinigen (UK)
- Ancillare (US)
- N-SIDE (Belgium)
- ADAllen (UK)
- Rubicon (India)
- Durbin (UK)
- Recipharm (Sweden)
- Seveillar (India)
- Myonex (India)
Research Coverage:
This report provides a detailed picture of the clinical trial supplies market. It aims at estimating the size and future growth potential of the market across different segments such as the service, end user, phases, therapeutic areas, type and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial supplies market and its sub segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, and opportunities.